HEAL DSpace

Red cells with paroxysmal nocturnal hemoglobinuria-phenotype in patients with acute leukemia

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Meletis, J en
dc.contributor.author Terpos, E en
dc.contributor.author Samarkos, M en
dc.contributor.author Meletis, C en
dc.contributor.author Apostolidou, E en
dc.contributor.author Komninaka, V en
dc.contributor.author Anargyrou, K en
dc.contributor.author Korovesis, K en
dc.contributor.author Mavrogianni, D en
dc.contributor.author Variami, E en
dc.contributor.author Viniou, N en
dc.contributor.author Konstantopoulos, K en
dc.date.accessioned 2014-03-01T01:51:58Z
dc.date.available 2014-03-01T01:51:58Z
dc.date.issued 2002 en
dc.identifier.issn 10245332 en
dc.identifier.uri https://dspace.lib.ntua.gr/xmlui/handle/123456789/26517
dc.relation.uri http://www.scopus.com/inward/record.url?eid=2-s2.0-0036290541&partnerID=40&md5=ecd851222fb1a63e7ce20d975761c58f en
dc.subject Acute lymphoblastic leukemia (ALL) en
dc.subject Acute non-lymphoblastic leukemia (ANLL) en
dc.subject Decay-accelerating factor (DAF en
dc.subject CD55) en
dc.subject Membrane inhibitor of reactivelysis (MIRL en
dc.subject CD59) en
dc.subject Paroxysmal nocturnal hemoglobinuria (PNH) en
dc.subject.other decay accelerating factor en
dc.subject.other antineoplastic agent en
dc.subject.other CD59 antigen en
dc.subject.other glycosylphosphatidylinositol en
dc.subject.other regulator protein en
dc.subject.other sucrose en
dc.subject.other acute disease en
dc.subject.other adolescent en
dc.subject.other adult en
dc.subject.other aged en
dc.subject.other article en
dc.subject.other blood en
dc.subject.other diagnostic procedure en
dc.subject.other disease course en
dc.subject.other erythrocyte en
dc.subject.other female en
dc.subject.other human en
dc.subject.other immunology en
dc.subject.other incidence en
dc.subject.other leukemia en
dc.subject.other male en
dc.subject.other middle aged en
dc.subject.other paroxysmal nocturnal hemoglobinuria en
dc.subject.other pathology en
dc.subject.other phenotype en
dc.subject.other acute lymphoblastic leukemia en
dc.subject.other acute nonlymphocytic leukemia en
dc.subject.other antigen expression en
dc.subject.other bone marrow en
dc.subject.other cancer classification en
dc.subject.other cell infiltration en
dc.subject.other cell membrane en
dc.subject.other cell population en
dc.subject.other controlled study en
dc.subject.other correlation analysis en
dc.subject.other hematologic disease en
dc.subject.other human cell en
dc.subject.other karyotype en
dc.subject.other major clinical study en
dc.subject.other medical literature en
dc.subject.other medical record en
dc.subject.other patient information en
dc.subject.other priority journal en
dc.subject.other treatment outcome en
dc.subject.other Acute Disease en
dc.subject.other Adolescent en
dc.subject.other Adult en
dc.subject.other Aged en
dc.subject.other Aged, 80 and over en
dc.subject.other Antigens, CD55 en
dc.subject.other Disease Progression en
dc.subject.other Erythrocytes en
dc.subject.other Female en
dc.subject.other Hemoglobinuria, Paroxysmal en
dc.subject.other Humans en
dc.subject.other Incidence en
dc.subject.other Leukemia en
dc.subject.other Male en
dc.subject.other Middle Aged en
dc.subject.other Molecular Diagnostic Techniques en
dc.subject.other Phenotype en
dc.title Red cells with paroxysmal nocturnal hemoglobinuria-phenotype in patients with acute leukemia en
heal.type journalArticle en
heal.publicationDate 2002 en
heal.abstract CD55 and CD59 are complement regulatory proteins that are linked to the cell membrane via a glycosyl-phosphatidylinositol anchor. They are reduced mainly in paroxysmal nocturnal hemoglobinuria (PNH) and in other hematological disorders. However, there are very few reports in the literature concerning their expression in patients with acute leukemias (AL). We studied the CD55 and CD59 expression in 88 newly diagnosed patients with AL [65 with acute non-lymphoblastic leukemia (ANLL) and 23 with acute lymphoblastic leukemia (ALL)] using the sephacryl gel test, the Ham and sucrose lysis tests and we compared the results with patients' clinical data and disease course. Eight patients with PNH were also studied as controls. Red cell populations deficient in both CD55 and CD59 were detected in 23% of ANLL patients (especially of M0, M2 and M6 FAB subtypes), 13% of ALL and in all PNH patients. CD55-deficient erythrocytes were found in 6 ANLL patients while the expression of CD59 was decreased in only 3 patients with ANLL. No ALL patient had an isolated deficiency of these antigens. There was no correlation between the existence of CD55 and/or CD59 deficiency and the percentage of bone marrow infiltration, karyotype or response to treatment. However no patient with M3, M5, M7 subtype of ANLL and mature B- or T-cell ALL showed a reduced expression of both antigens. The deficient populations showed no alteration after chemotherapy treatment or during disease course. This study provides evidence about the lower expression of CD55 and CD59 in some AL patients and the correlation with their clinical data. The possible mechanisms and the significance of this phenotype are discussed. en
heal.journalName Hematology en
dc.identifier.volume 7 en
dc.identifier.issue 2 en
dc.identifier.spage 69 en
dc.identifier.epage 74 en


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record